Glow + KPV · usually 50/10/10/10 mg
Klow Blend
Blend
What it is
Klow (KLOW) is Glow plus KPV. A common vial is GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg (80 mg total). Shops pitch it as Glow with an extra anti-inflammatory fragment.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- What people want: repair + skin + a calmer inflammatory tone from KPV, one vial.
- Coremend is a different trio: more TB-500, plus BPC and KPV, no GHK-Cu.
- Four drugs in one syringe means four caveats and zero independent dose control.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Union of GHK-Cu matrix signaling, BPC cytoprotection, TB-500 migration, and KPV (α-MSH fragment) NF-κB / barrier talk. Still not a studied tetramer drug.
Possible side effects / caveats
Copper site issues plus whatever each part can do. Harder to tell which component caused a reaction.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Common vendor vial | 50 / 10 / 10 / 10 mg (GHK-Cu / BPC / TB-500 / KPV) | 80 mg total | Confirm the COA split |
| See also | Glow, Coremend, KPV | Family of blends |